NASDAQ:VRCA - Verrica Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.57 -1.66 (-10.90 %)
(As of 11/15/2018 03:52 AM ET)
Previous Close$15.23
Today's Range$13.11 - $15.40
52-Week Range$11.41 - $23.29
Volume120,000 shs
Average Volume61,892 shs
Market Capitalization$359.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is headquartered in West Chester, Pennsylvania.

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
Previous Symbol
CUSIPN/A
Phone484-453-3300

Debt

Debt-to-Equity RatioN/A
Current Ratio40.27
Quick Ratio40.27

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.75 per share
Price / Book3.62

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-4,450,000.00
Net MarginsN/A
Return on Equity-35.15%
Return on Assets-26.46%

Miscellaneous

Employees11
Outstanding Shares25,700,000
Market Cap$359.75 million
OptionableNot Optionable

Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) posted its earnings results on Wednesday, November, 7th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.03. View Verrica Pharmaceuticals' Earnings History.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Verrica Pharmaceuticals.

What price target have analysts set for VRCA?

3 brokers have issued 12 month price objectives for Verrica Pharmaceuticals' shares. Their forecasts range from $24.00 to $35.00. On average, they anticipate Verrica Pharmaceuticals' share price to reach $28.3333 in the next twelve months. This suggests a possible upside of 108.8% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals.

What is the consensus analysts' recommendation for Verrica Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals.

Has Verrica Pharmaceuticals been receiving favorable news coverage?

News articles about VRCA stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a news impact score of 0.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days.

Who are some of Verrica Pharmaceuticals' key competitors?

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the folowing people:
  • Mr. Ted White, Pres, CEO & Director (Age 53)
  • Mr. Chris Degnan, Chief Financial Officer (Age 38)
  • Ms. Linda S. Palczuk, Chief Operating Officer (Age 56)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 54)
  • Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 46)

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

When does the company's lock-up period expire?

Verrica Pharmaceuticals' lock-up period expires on Wednesday, December 12th. Verrica Pharmaceuticals had issued 5,000,000 shares in its public offering on June 15th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (2.51%), BlackRock Inc. (0.99%), Kornitzer Capital Management Inc. KS (0.84%), FIL Ltd (0.70%), Gilder Gagnon Howe & Co. LLC (0.65%) and Sphera Funds Management LTD. (0.46%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning and Ted White. View Institutional Ownership Trends for Verrica Pharmaceuticals.

Which institutional investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FIL Ltd and Sphera Funds Management LTD.. View Insider Buying and Selling for Verrica Pharmaceuticals.

Which institutional investors are buying Verrica Pharmaceuticals stock?

VRCA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Kornitzer Capital Management Inc. KS, Gilder Gagnon Howe & Co. LLC, Asymmetry Capital Management L.P. and Bank of New York Mellon Corp. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning and Ted White. View Insider Buying and Selling for Verrica Pharmaceuticals.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $13.57.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $359.75 million. Verrica Pharmaceuticals employs 11 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is http://www.verrica.com.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 North High Street Suite 200, West Chester PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]


MarketBeat Community Rating for Verrica Pharmaceuticals (NASDAQ VRCA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  44
MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel